Sienna Biopharmaceuticals, Inc.
SNNAQ · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.03 | -0.05 |
| FCF Yield | -290.37% | -31.26% | -21.90% | -32.33% |
| EV / EBITDA | 0.59 | -1.01 | -1.96 | -1.51 |
| Quality | ||||
| ROIC | -6.61% | -8.90% | -17.10% | -23.78% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 4.49 | 1.02 | 0.78 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -112.00% | 34.10% | 18.15% | 1.89% |
| Safety | ||||
| Net Debt / EBITDA | 1.29 | 2.50 | 1.73 | 0.93 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |